

Review

Not peer-reviewed version

Unlocking the Anti-Obesity Potential of the Genus *Scutellaria*: Pharmacological Insights and Therapeutic Perspectives

[Asfaraeni Rahmah](#), [Kurnia Agustini](#), [Anton Bahtiar](#) *

Posted Date: 9 May 2026

doi: 10.20944/preprints202605.0610.v1

Keywords: *Scutellaria*; anti-obesity; flavonoids; adipogenesis; lipid metabolism; phytochemicals; metabolic regulation



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC, OpenAlex.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

Unlocking the Anti-Obesity Potential of the Genus *Scutellaria*: Pharmacological Insights and Therapeutic Perspectives

Asfaraeni Rahmah¹, Kurnia Agustini² and Anton Bahtiar^{1,*}

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Gedung Fakultas Farmasi Kampus UI Depok 16424, Indonesia

² Research Center for Pharmaceutical Ingredient and Traditional Medicine, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, 16915, Indonesia

* Correspondence: anton.bahtiar@farmasi.ui.ac.id

Abstract

Obesity represents a growing global health challenge, driving the need for safer and more effective therapeutic strategies. Natural products, particularly medicinal plants, have gained increasing attention as potential sources of anti-obesity agents due to their diverse bioactive compounds and multi-target mechanisms. The genus *Scutellaria* (Lamiaceae) is rich in phytochemicals, especially flavonoids such as baicalin, baicalein, and wogonin, which have been reported to modulate key metabolic pathways involved in obesity. This review aims to comprehensively summarize current evidence on selected *Scutellaria* species with potential anti-obesity activity, focusing on their phytochemical profiles and pharmacological mechanisms. A literature search was conducted using PubMed, Scopus, and Google Scholar databases, and relevant studies were selected based on predefined inclusion criteria. The findings indicate that *Scutellaria*-derived compounds may exert anti-obesity effects through multiple mechanisms, including inhibition of adipogenesis, regulation of lipid metabolism, improvement of energy homeostasis, and suppression of obesity-associated inflammation. Preclinical studies provide substantial evidence supporting these biological activities; however, clinical validation remains limited. In conclusion, *Scutellaria* species represent promising candidates for the development of novel anti-obesity therapies. Further studies, particularly well-designed clinical trials, are necessary to confirm their efficacy, safety, and therapeutic applicability in humans.

Keywords: *Scutellaria*; anti-obesity; flavonoids; adipogenesis; lipid metabolism; phytochemicals; metabolic regulation

1. Introduction

Obesity has become a major global public health concern, with its prevalence increasing markedly across diverse regions. Recent reports highlight a continuous rise in obesity rates, particularly in the Americas and Europe, where the burden remains among the highest worldwide [1]. Projections from the World Obesity Atlas further indicate a substantial increase in the number of individuals affected in the coming decades, underscoring the escalating scale of this health challenge [2]. In addition, obesity is strongly associated with a wide range of comorbidities, including type 2 diabetes, cardiovascular diseases, and metabolic syndrome, thereby emphasizing the urgent need for effective prevention and management strategies [3].

Pharmacological interventions are widely employed in the management of obesity; Nevertheless, currently available therapies present several limitations. Many synthetic anti-obesity agents exhibit variable efficacy and are often associated with adverse effects, particularly involving the gastrointestinal and pancreatic systems [4,5]. Furthermore, high treatment costs and limited

accessibility remain significant barriers, especially in low- and middle-income populations [6,7]. These challenges have driven ongoing efforts to identify safer, more effective, and more accessible therapeutic alternatives targeting obesity-related metabolic disturbances.

In this context, phytochemical compounds derived from medicinal plants have attracted considerable attention due to their potential roles in metabolic regulation. Bioactive classes such as flavonoids, polyphenols, and alkaloids have been reported to influence key processes involved in obesity, including adipogenesis, lipid metabolism, and energy homeostasis [8–11]. Preclinical evidence suggests that these plant-derived compounds may improve metabolic parameters by modulating molecular pathways associated with fat accumulation and energy balance [12,13]. Such findings support the continued exploration of plant-based compounds as promising sources of novel anti-obesity agents.

Among these, the genus *Scutellaria* (family *Lamiaceae*) has gained increasing scientific interest due to its rich and diverse phytochemical composition. Notably, flavonoids such as baicalin, baicalein, and wogonin have been widely studied for their biological activities [12–15]. These compounds have been reported to regulate adipocyte differentiation, modulate lipid metabolism, and attenuate inflammatory processes involved in obesity pathogenesis. Moreover, accumulating evidence indicates that extracts and isolated constituents from *Scutellaria* species can influence key metabolic pathways related to lipid accumulation and energy regulation [14,16,17].

Therefore, this review aims to comprehensively summarize current studies on selected *Scutellaria* species and evaluate their potential as anti-obesity agents, with particular emphasis on their bioactive compounds and underlying mechanisms of action in obesity-related metabolic pathways.

2. Methods

A comprehensive literature search was conducted to identify studies investigating the phytochemistry and anti-obesity potential of *Scutellaria* species. Electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, were systematically searched for relevant articles published up to 2026. The search strategy employed combinations of keywords such as “*Scutellaria*”, “skullcap”, “anti-obesity”, “antiobesity”, “adipogenesis”, “lipid metabolism”, “flavonoids”, “baicalin”, “baicalein”, and “wogonin”. Additional records were identified through manual screening of reference lists from relevant articles.

The study selection process was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 2,798 records were initially identified, including 2,687 records from electronic databases and 111 additional records from other sources. After removal of duplicates, 1,351 records remained for title and abstract screening.

During the screening phase, 871 records were excluded based on irrelevance to the topic. The remaining 498 full-text articles were assessed for eligibility. Of these, 334 articles were excluded for the following reasons: lack of relevance to obesity (n = 167), insufficient mechanistic or experimental detail (n = 113), non-English language (n = 17), and duplication or overlap with previously included reviews (n = 37).

Ultimately, 164 studies were included in the qualitative synthesis. Data from the selected studies were extracted and categorized according to *Scutellaria* species, phytochemical constituents, experimental models, and reported anti-obesity mechanisms. The findings were then synthesized narratively, with emphasis on mechanistic insights and critical evaluation of the available evidence.




Figure 1. PRISMA flow diagram showing the process of literature identification, screening, eligibility assessment, and inclusion. A total of 2,798 records were initially identified, with 1,351 remaining after duplicate removal. Following title and abstract screening, 498 articles were assessed for full-text eligibility, and 164 studies were ultimately included in the qualitative synthesis.

3. The Genus *Scutellaria*

The figure illustrates the remarkable morphological diversity within the genus *Scutellaria*, particularly in terms of floral architecture, pigmentation, and inflorescence arrangement. Despite sharing the characteristic bilabiate corolla and the distinctive dorsal appendage (scutellum), individual species exhibit substantial variation in flower size, color spectrum (ranging from white and yellow to deep purple and red), and structural complexity. This diversity reflects the broad ecological adaptability of the genus and its evolutionary radiation across different geographical regions [18–22].

From a taxonomic perspective, floral morphology remains a key diagnostic feature for species identification within *Scutellaria*. Variations in corolla shape, calyx structure, and reproductive organs contribute to species differentiation, although these traits may sometimes overlap, complicating classification. Recent phylogenomic studies suggest that morphological diversity within the genus is not always congruent with genetic relationships, indicating potential convergent evolution driven by environmental and pollination pressures [23,24].




Figure 2. Morphological and geographic diversity of genus *Scutellaria*. **(A)** Floral diversity of 24 representative species showing variation in color and inflorescence architecture. **(B)** Diagnostic floral and vegetative characters typical of *Scutellaria*. **(C)** Global distribution pattern of the genus, with the highest species richness in East Asia. **Species list:** (1) *S. baicalensis*, (2) *S. barbata*, (3) *S. lateriflora*, (4) *S. galericulata*, (5) *S. miqueliana*, (6) *S. indica*, (7) *S. discolor*, (8) *S. orientalis*, (9) *S. tsinyuensis*, (10) *S. rubescens*, (11) *S. przewalskii*, (12) *S. amoena*, (13) *S. saxatilis*, (14) *S. setifera*, (15) *S. rivularis*, (16) *S. atropurpurea*, (17) *S. wrightii*, (18) *S. altissima*, (19) *S. brevicalyx*, (20) *S. umbrosa*, (21) *S. yunnanensis*, (22) *S. chinensis*, (23) *S. nelsonii*, (24) *S. strigillosa*.

In the Indonesia endemic *Scutellaria slametensis*, differences in flower were observed between individuals from Cibodas Botanical Garden and Baturraden Botanical Garden. This variation may be related to environmental factors such as altitude, temperature, and light, as well as pollination pressure.

Notably, morphological variation may also have implications for phytochemical diversity. Differences in plant organs, particularly between aerial parts and roots, have been associated with distinct profiles of secondary metabolites, including flavonoids, terpenoids, and phenolic compounds. As these metabolites underpin the pharmacological activities of *Scutellaria* species, including their proposed anti-obesity effects, morphological diversity may indirectly reflect biochemical and functional heterogeneity within the genus [25].

However, current research rarely integrates morphological, phytochemical, and pharmacological data in a systematic manner. Most studies focus on a limited number of species, particularly *S. baicalensis*, without considering broader interspecies variation. This represents a critical gap, as comparative analyses across morphologically distinct species could provide valuable insights into structure–activity relationships and aid in the identification of novel bioactive compounds.

Overall, the diversity depicted in this figure underscores the complexity of the genus *Scutellaria* and highlights the need for integrative approaches that combine taxonomy, phytochemistry, and pharmacology to fully elucidate its therapeutic potential.



Figure 3. Variation in flower coloration of *Scutellaria slametensis*. (D1) Plant growing in its natural habitat on *Mt. Slamet* (in situ). (D2) Specimens collected from Cibodas Botanical Garden showing predominantly purplish flowers. (D3) Specimen from Baturraden Botanical Garden (ex situ collection) showing pinkish flowers.

4. Phytochemical Constituents of Selected *Scutellaria* Species

Species within the genus *Scutellaria* exhibit considerable chemical heterogeneity, reflecting variations in geographic distribution, plant part, and extraction methodologies [26–28]. Among the identified metabolites, flavonoids constitute the dominant class, accompanied by phenolic acids, terpenoids, iridoids, and other secondary metabolites. These compounds collectively contribute to the diverse biological activities attributed to the genus.

Despite this, despite extensive phytochemical characterization, the available data remain unevenly distributed across species, with a disproportionate focus on a limited number of well-studied taxa, particularly *S. baicalensis*. In addition, inconsistencies in analytical approaches and reporting standards complicate direct comparison between studies.

The phytochemical diversity of the genus *Scutellaria* is extensive and encompasses numerous species with distinct metabolite profiles. To improve clarity and emphasize the most pharmacologically relevant taxa, Table 1 summarizes representative *Scutellaria* species frequently investigated for their bioactive constituents and metabolic regulatory potential. A comprehensive phytochemical inventory of additional *Scutellaria* species is provided in Supplementary Table S1.

Table 1. Representative phytochemical profiles of selected *Scutellaria* species (condensed and standardized).

Species	Plant Part	Dominant Phytochemical Classes	Representative Compounds	References
<i>S. baicalensis</i>	Root, aerial	Flavonoids, terpenoids	phenolics, Baicalin, wogonin, wogonoside	baicalein, [29–34]
<i>S. barbata</i>	Root, aerial	Diterpenoids, volatiles	flavonoids, Scutellarin, clerodanes	luteolin, neo-[30,33,35,36]
<i>S. lateriflora</i>	Aerial tissue	Flavonoids, derivatives	indole Baicalin, verbascoside	scutellarin, [30,37–40]
<i>S. adenostegia</i>	Aerial, root	Flavonoids, volatiles	Apigenin, baicalein	luteolin, [41,42]

<i>S. albida</i>	Aerial	Iridoids, phenylethanoids, Catalpol, flavonoids	scutellarin	verbascoside, [44-46]
<i>S. alpina</i>	Callus, aerial	Flavonoids, terpenoids	Baicalin, wogonoside	luteolin, [47,48]
<i>S. altissima</i>	Root, aerial	Flavonoids, phenylpropanoids	Baicalin, wogonin, oroxylin A	luteolin, myristicin [33,49-51]
<i>S. amoena</i>	Aerial	Flavonoids	Baicalin, wogonin, oroxylin A	[53]
<i>S. araxensis</i>	Root, aerial	Flavonoids, phenolics	Chrysin, wogonin, tricetin	iridoids, [55-57]
<i>S. bornmuelleri</i>	Root, aerial	Flavonoids, phenylethanoids	Wogonin, verbascoside	baicalin, [55,61,62]
<i>S. galericulata</i>	Aerial	Flavonoids, diterpenoids	Wogonin, baicalein	scutellarein, [75-77]
<i>S. indica</i>	Aerial, root	Flavonoids	Baicalin, naringenin	wogonin, [34,92,93]
<i>S. multicaulis</i>	Root, aerial	Flavonoids, terpenoids	Pectolinarin, wogonin	chrysin, [69,97]
<i>S. orientalis</i>	Root, aerial	Flavonoids, volatiles	Baicalein, scutellarin	chrysin, [55,97,101,102]
<i>S. rivularis</i>	Aerial	Flavonoids, diterpenoids	Baicalin, scutellone D	baicalein, [115,116]
<i>S. scordiifolia</i>	Aerial	Flavonoid glycosides	Scutellarein derivatives	[122]
<i>S. viscidula</i>	Aerial, root	Flavonoids	Baicalin, viscidulin	wogonin, [126]
<i>S. wrightii</i>	Aerial, root	Flavonoids	Chrysin, scutellarin	baicalin, [33]

Although *Scutellaria* species contain a broad range of phytochemicals, current anti-obesity evidence is concentrated primarily on flavonoids from *S. baicalensis*, particularly baicalin, baicalein, and wogonin. These compounds appear to act through multi-target mechanisms, including suppression of adipogenesis, activation of AMPK-mediated lipid catabolism, inhibition of inflammatory signaling, and improvement of insulin sensitivity. Despite this most findings remain preclinical, and differences in experimental models, extract standardization, dose selection, and compound bioavailability limit direct translational interpretation.

As summarized in Table 2, AMPK activation appears to be one of the most consistently reported mechanism and the major proposed anti-obesity mechanisms of *Scutellaria*-derived compounds and highlights the current evidentiary limitations. Table 2 also highlights the predominance of cellular and animal models in anti-obesity research.

Table 2. Anti-obesity mechanisms of major *Scutellaria*-derived compounds and extracts.

Compound/Extract	Source species	Experimental model	Main anti-obesity mechanism	Reported metabolic effects	Critical note
Baicalin	<i>S. baicalensis</i> , several <i>Scutellaria</i> spp	3T3-L1 adipocytes; HFD-induced obese models	Activation of AMPK/ACC pathway; Reduced lipid suppression of lipogenesis; promotion of thermogenesis and UCP1 upregulation and browning pathways; activation of hepatic CPT1-	of accumulation, adipocyte hypertrophy, lipid deposition, and body-weight gain	Strong preclinical evidence, but limited human validation

			mediated fatty acid β -oxidation [128–131] Inhibition of adipogenesis via downregulation of PPAR γ /C/EBP α and Suppression of mTOR signaling; reduction of differentiation (SREBP-1, n and Nrf-2 intracellular triglyceride accumulation) activation of adipose tissue macrophages [132–134]	Mechanistic evidence predominantly cellular, with limited in vivo validation
Baicalein	S. <i>baicalensis</i> several <i>Scutellaria</i> spp	Adipocytes; metabolic diseases; Western diet-induced obese mice		
	S. <i>baicalensis</i> several <i>Scutellaria</i> spp	Adipocytes; obesity-associated inflammation models	Improved inflammatory profile, glucose and lipid regulation [135–137]	Promising, but often studied in combination or non-obesity models
Wogonin	S. <i>baicalensis</i> several <i>Scutellaria</i> spp	Adipocytes; obesity-associated inflammation models	Regulation of lipid metabolism and inflammatory mediators [138,139]	Potential improvement in metabolic dysfunction and adipose inflammation
Wogonoside/Norwogonoside	S. <i>baicalensis</i> several <i>Scutellaria</i> spp	Preclinical metabolic models	Inhibition of adipogenesis and oxidative-inflammatory signaling; enhancement of autophagy suppression of IRE1 α /XBP1-mediated lipogenesis [140–142]	Anti-obesity-specific data remain less extensive than baicalin
Scutellarin / Scutellarein	S. <i>baicalensis</i> several <i>Scutellaria</i> spp	Adipocyte and metabolic models	Modulation of lipid metabolism, oxidative stress, and inflammatory pathways [143–145]	Reduced lipid accumulation and obesity-related inflammation validation
Oroxylin A	S. <i>baicalensis</i> several <i>Scutellaria</i> spp	In vitro and preclinical models	Downregulation of adipogenic transcription factors; antioxidant activity [146–148]	Poor bioavailability may limit translational relevance
Chrysin	Several <i>Scutellaria</i> spp.	Adipocyte and metabolic models	Inhibition of adipocyte differentiation; AMPK-related lipid regulation [149–151]	Reduced lipid accumulation and improved metabolic signaling Not unique to <i>Scutellaria</i> ; attribution should be cautious
Apigenin	S. <i>adenostegia</i> , <i>S. araxensis</i>	Adipocytes; metabolic models		

Luteolin	<i>S. adenostegia</i> , <i>S. altissima</i>	Adipocyte and inflammation models	Anti-inflammatory activity; regulation of adipogenesis and lipid metabolism [152,153]	Suppressed adipocyte differentiation and inflammatory mediator production Improved insulin	Needs species-specific obesity confirmation
<i>S. baicalensis</i> extract	<i>S. baicalensis</i>	HFD-induced obesity; resistance models	Regulation of inflammation, insulin metabolism, insulin signaling [154,155]	adiposeresistance, lipidreduced andinflammatory markers, and improved metabolic parameters Reduced adipogenesis;	Extract composition varies across studies
<i>S. baicalensis</i> + <i>Phyllostachys pubescens</i> combination	<i>S. baicalensis</i>	3T3-L1 adipocytes; HFD-induced obese mice	AMPK activation; browning/thermogenesis enhancement [156]	increased thermogenic markers and energy expenditure	Combination design limits attribution to <i>Scutellaria</i> alone
<i>S. barbata</i> constituents	<i>S. barbata</i>	Mostly obesity pharmacological models	non-Anti-inflammatory, antioxidant, and metabolic regulatory potential [157,158]	Possible relevance to obesity-associated inflammation	Direct anti-obesity evidence remains limited
<i>S. lateriflora</i>	<i>S. lateriflora</i>	Anti-inflammatory models, primarily neuropharmacology	Putative AMPK, anti-inflammatory metabolic modulation, antioxidant [159,160]	Possible relevance to obesity-associated inflammation	No direct anti-obesity evidence
<i>S. indica</i> constituents	<i>S. indica</i>	Mostly obesity pharmacological models, validated specific model reported	non- Putative metabolic regulation noantioxidant, anti-obesity-inflammatory activity [161,162]	Possible relevance to anti-obesity-associated inflammation	No direct anti-obesity evidence
<i>S. galericulata</i> constituents	<i>S. galericulata</i>	Non-obesity inflammatory models	Antiinflammatory activity via suppression of TNF- α , IL-6, IL-8 [163,164]	Possible relevance to obesity-associated inflammation	No direct anti-obesity evidence
<i>Scutellaria</i> constituents	Several spp <i>scutellaria</i> spp	Non-obesity inflammatory models	Antioxidant effect	Possible relevance to obesity-associated oxidative stress	No direct anti-obesity evidence

5. Results and Discussion

The included studies were analyzed and synthesized based on phytochemical composition and underlying anti-obesity mechanisms, as summarized below.

5.1. Phytochemical Drivers of Anti-Obesity Activity

The anti-obesity potential of *Scutellaria* species is largely attributed to their rich flavonoid content, particularly baicalin, baicalein, and wogonin, which have been consistently identified across multiple species. These compounds represent structurally related flavones that exhibit broad biological activities, including modulation of metabolic and inflammatory pathways relevant to obesity. In addition to flavonoids, other classes such as phenolic acids, terpenoids, and iridoids may contribute synergistically; Conversely, their roles remain comparatively underexplored.

A notable limitation across the literature is the predominant focus on a small subset of compounds, particularly those derived from *S. baicalensis*, while many other species remain chemically characterized but pharmacologically underinvestigated. This imbalance restricts the ability to generalize findings across the genus and suggests that the therapeutic potential of less-studied *Scutellaria* species may be underestimated.

5.2. Modulation of Adipogenesis and Lipid Metabolism

A central mechanism underlying the anti-obesity effects of *Scutellaria*-derived compounds is the regulation of adipogenesis. Several studies report that baicalin, baicalein, and related flavonoids inhibit adipocyte differentiation through downregulation of key transcription factors, including peroxisome proliferator-activated receptor gamma (PPAR γ) and CCAAT/enhancer-binding proteins (C/EBPs). These transcription factors play critical roles in adipocyte maturation and lipid accumulation, and their suppression is associated with reduced adipogenesis in in vitro models.

In parallel, these compounds have been shown to influence lipid metabolism by activating AMP-activated protein kinase (AMPK), a central regulator of cellular energy homeostasis. Activation of AMPK promotes fatty acid oxidation while inhibiting lipogenesis, thereby contributing to reduced lipid accumulation in adipose and hepatic tissues. While these findings are mechanistically consistent, they are largely derived from controlled experimental systems, and their physiological relevance in humans remains to be fully established.

5.3. Anti-Inflammatory and Metabolic Regulatory Effects

Chronic low-grade inflammation is a hallmark of obesity and contributes significantly to metabolic dysfunction. *Scutellaria*-derived flavonoids, particularly wogonin and baicalein, have demonstrated anti-inflammatory properties through the suppression of pro-inflammatory cytokines and signaling pathways, including NF- κ B. These effects may indirectly improve insulin sensitivity and metabolic homeostasis.

Despite this, the distinction between primary anti-obesity effects and secondary anti-inflammatory benefits is often unclear. Many studies do not differentiate whether observed metabolic improvements result from direct modulation of adipose tissue biology or from broader systemic anti-inflammatory effects. This ambiguity highlights the need for more targeted mechanistic studies to clarify causality.

5.4. Energy Homeostasis and Thermogenic Regulation

Emerging evidence suggests that certain *Scutellaria* extracts may influence energy expenditure by promoting thermogenesis and adipose tissue browning, potentially via AMPK-related pathways. Such effects represent a promising mechanism, as they address energy imbalance rather than solely inhibiting fat accumulation. Nonetheless, these findings are relatively limited and often involve combination extracts or multi-component formulations, making it difficult to attribute specific effects to individual *Scutellaria*-derived compounds.

5.5. Clinical Perspective

Despite substantial preclinical evidence, clinical evaluation of *Scutellaria*-derived compounds in obesity remains extremely limited. Current human studies primarily focus on the anti-inflammatory, hepatoprotective, or metabolic effects of *Scutellaria baicalensis* formulations rather than obesity-

specific endpoints. Moreover, issues related to compound bioavailability, pharmacokinetic variability, and extract standardization continue to complicate clinical translation. Consequently, the therapeutic relevance of *Scutellaria* in obesity management remains largely unvalidated in human populations.

6. Translational Limitations and Research Gaps

Despite promising preclinical findings, several critical limitations hinder the translation of *Scutellaria* research into clinical application. First, the majority of studies are restricted to in vitro systems or animal models, with a notable lack of well-designed human trials. Second, variability in extraction methods, compound purity, and dosing regimens reduces reproducibility and comparability across studies. Third, issues related to bioavailability and pharmacokinetics of key flavonoids, such as baicalin and chrysin, remain insufficiently addressed, raising concerns about their in vivo efficacy.

Additionally, the frequent use of multi-component extracts complicates the identification of active constituents and their precise mechanisms of action. While synergistic effects are often proposed, they are rarely systematically evaluated. This gap underscores the importance of integrating phytochemical standardization with mechanistic and clinical research.

7. Implications for Future Research

To advance the therapeutic potential of *Scutellaria* species, future studies should prioritize standardized extraction protocols, comparative analyses across species, and detailed pharmacokinetic profiling of key compounds. Furthermore, well-designed clinical trials are essential to validate preclinical findings and assess safety, efficacy, and optimal dosing strategies. Expanding research beyond *S. baicalensis* to include underexplored species may also uncover novel bioactive compounds with distinct or complementary mechanisms of action.

8. Synthesis

Collectively, current evidence suggests that *Scutellaria*-derived compounds exert anti-obesity effects through multi-target mechanisms, including inhibition of adipogenesis, modulation of lipid metabolism, suppression of inflammation, and potential regulation of energy expenditure. Nevertheless, the predominance of preclinical data, coupled with methodological inconsistencies and limited clinical validation, underscores the need for a more rigorous and integrative research approach. Addressing these challenges will be essential to fully elucidate the role of *Scutellaria* as a viable source of anti-obesity therapeutics.




Figure 4. Graphical conclusion and Future perspectives.

9. Conclusions

The genus *Scutellaria* represents a promising yet underutilized source of bioactive compounds with potential applications in obesity management. Accumulating evidence indicates that *Scutellaria*-derived flavonoids, particularly baicalin, baicalein, and wogonin, exert multi-target effects on key pathways involved in obesity pathogenesis, including the regulation of adipogenesis, lipid metabolism, inflammation, and energy homeostasis. These findings support the concept that plant-derived compounds may offer a complementary or alternative approach to conventional anti-obesity therapies.

However, despite encouraging preclinical data, the current body of evidence remains limited by several critical challenges. Research efforts are disproportionately focused on a small number of species, primarily *Scutellaria baicalensis*, while the pharmacological potential of many other species within the genus remains largely unexplored. In addition, methodological inconsistencies, including variability in extraction procedures, compound standardization, and experimental models, hinder cross-study comparability and reproducibility. Critically, the lack of well-designed clinical studies represents a major barrier to translating preclinical findings into therapeutic applications.

Future research should prioritize systematic phytochemical profiling across a broader range of *Scutellaria* species, alongside standardized experimental frameworks to enable more robust comparisons. Elucidation of pharmacokinetic properties, bioavailability, and safety profiles of key compounds is essential to bridge the gap between experimental efficacy and clinical applicability. Moreover, integrative approaches combining phytochemistry, molecular pharmacology, and clinical investigation will be critical for identifying lead compounds and validating their therapeutic potential.

In conclusion, while *Scutellaria* species exhibit considerable promise as sources of anti-obesity agents, their translation into clinically relevant therapies requires a more rigorous, standardized, and multidisciplinary research strategy. Addressing these challenges will be essential to fully realize the therapeutic value of this chemically and biologically diverse genus.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org.

Author Contributions: All the authors contributed equally to preparing and executing the idea for the article, design of the review, English language editing and formatting the article.

Acknowledgments: The authors declare no acknowledgements.

Conflicts of Interest: No potential conflict of interest was reported.

References

1. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. *Metabolism*. 2022 Aug 1;133:155217. doi:10.1016/J.METABOL.2022.155217 PubMed PMID: 35584732.
2. Powis J, Thompson R, Jackson-Leach R. World Obesity Atlas 2025 [Internet]. 2025 [cited 2026 Apr 27];1. Available from: www.worldobesity.org
3. Chong B, Jayabaskaran J, Kong G, Chan YH, Chin YH, Goh R, et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019. *EClinicalMedicine*. 2023 Mar 1;57. doi:10.1016/J.ECLINM.2023.101850 PubMed PMID: 36864983.
4. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine*. 2021 Mar 18;384(11):989–1002. doi:10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDF PubMed PMID: 33567185.
5. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *New England Journal of Medicine*. 2022 Jul 21;387(3):205–16. doi:10.1056/NEJMOA2206038/SUPPL_FILE/NEJMOA2206038_DATA-SHARING.PDF PubMed PMID: 35658024.
6. Gómez Lumbreras A, Tan MS, Villa-Zapata L, Ilham S, Earl JC, Malone DC. Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. *Nutr Metab Cardiovasc Dis*. 2023 Jun 1;33(6):1268–76. doi:10.1016/J.NUMECD.2023.03.012 PubMed PMID: 37088648.
7. Alsuhibani AA, Alrasheed MA, Alhomoud IS, Alsahali S, Almalki ZS, Guo JJ. Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023. *Front Med (Lausanne)*. 2025;12:1537181. doi:10.3389/FMED.2025.1537181/FULL
8. Varshney S, Kumar D, Choudhary R, Gupta A, Beg M, Shankar K, et al. Flavopiridol inhibits adipogenesis and improves metabolic homeostasis by ameliorating adipose tissue inflammation in a diet-induced obesity model. *Biomedicine & Pharmacotherapy*. 2024 Oct 1;179:117330. doi:10.1016/J.BIOPHA.2024.117330 PubMed PMID: 39208666.
9. Kim JH, Lee S, Cho EJ. Flavonoids from *Acer okamotoanum* Inhibit Adipocyte Differentiation and Promote Lipolysis in the 3T3-L1 Cells. *Molecules* 2020, Vol 25, Page 1920. 2020 Apr 21;25(8):1920. doi:10.3390/MOLECULES25081920 PubMed PMID: 32326254.
10. Casado-díaz A, Rodríguez-ramos Á, Torrecillas-baena B, Dorado G, Quesada-gómez JM, Gálvez-moreno MÁ. Flavonoid Phloretin Inhibits Adipogenesis and Increases OPG Expression in Adipocytes Derived from Human Bone-Marrow Mesenchymal Stromal-Cells. *Nutrients*. 2021 Nov 1;13(11). doi:10.3390/NU13114185 PubMed PMID: 34836440.
11. Sung YY, Son E, Im G, Kim DS. Herbal Combination of *Phyllostachys pubescens* and *Scutellaria baicalensis* Inhibits Adipogenesis and Promotes Browning via AMPK Activation in 3T3-L1 Adipocytes. *Plants*. 2020 Nov 1;9(11):1422. doi:10.3390/PLANTS9111422 PubMed PMID: 33114092.
12. Lin Y, Ren N, Li S, Chen M, Pu P. Novel anti-obesity effect of scutellarein and potential underlying mechanism of actions. *Biomedicine & Pharmacotherapy*. 2019 Sep 1;117:109042. doi:10.1016/J.BIOPHA.2019.109042 PubMed PMID: 31228804.
13. Li H, Tang S. Baicalin attenuates diet-induced obesity partially through promoting thermogenesis in adipose tissue. *Obes Res Clin Pract*. 2021 Sep 1;15(5):485–90. doi:10.1016/J.ORCP.2021.08.003 PubMed PMID: 34465552.

14. Li H, Tang S. Baicalin attenuates diet-induced obesity partially through promoting thermogenesis in adipose tissue. *Obes Res Clin Pract.* 2021 Sep 1;15(5):485–90. doi:10.1016/J.ORCP.2021.08.003 PubMed PMID: 34465552.
15. Baygildieva DI, Baygildiev TM, Stavrianidi AN, Shpigun OA, Rodin IA. Simultaneous Determination of Wogonin, Scutellarin, Baicalin, and Baicalein in Extracts from *Scutellariae Baicalensis* by High-Performance Liquid Chromatography with Tandem Mass Spectrometry. *Journal of Analytical Chemistry.* 2018 Dec 20;73(14):1317–22. doi:10.1134/S1061934818140022
16. Yang L Le, Xiao N, Liu J, Liu K, Liu B, Li P, et al. Differential regulation of baicalin and scutellarin on AMPK and Akt in promoting adipose cell glucose disposal. *Biochim Biophys Acta Mol Basis Dis.* 2017 Feb 1;1863(2):598–606. doi:10.1016/J.BBADIS.2016.11.024 PubMed PMID: 27903431.
17. Zhang Z, Wang R, Cai J, Li X, Feng X, Xu S, et al. Baicalin alleviates lipid accumulation in adipocytes via inducing metabolic reprogramming and targeting Adenosine A1 receptor. *Toxicon.* 2025 Apr 1;258:108339. doi:10.1016/J.TOXICON.2025.108339 PubMed PMID: 40188992.
18. Wang D, Wang J, Wang Y, Yao D, Niu Y. Metabolomic and Transcriptomic Profiling Uncover the Underlying Mechanism of Color Differentiation in *Scutellaria baicalensis* Georgi. *Flowers.* *Front Plant Sci.* 2022 Jun 9;13:884957. doi:10.3389/FPLS.2022.884957/TEXT
19. Guo F, Guan R, Sun X, Zhang C, Shan C, Liu M, et al. Integrated metabolome and transcriptome analyses of anthocyanin biosynthesis reveal key candidate genes involved in colour variation of *Scutellaria baicalensis* flowers. *BMC Plant Biol.* 2023 Dec 1;23(1):643-. doi:10.1186/S12870-023-04591-3/FIGURES/10 PubMed PMID: 38097929.
20. Costine B, Zhang M, Chhajed S, Pearson B, Chen S, Nadakuduti SS. Exploring native *Scutellaria* species provides insight into differential accumulation of flavones with medicinal properties. *Scientific Reports* 2022 12:1. 2022 Aug 1;12(1):13201-. doi:10.1038/s41598-022-17586-1 PubMed PMID: 35915209.
21. Wang Y, Xu C, Guo X, Wang Y, Chen Y, Shen J, et al. Phylogenomics analysis of *Scutellaria* (Lamiaceae) of the world. *BMC Biol.* 2024 Dec 1;22(1):185-. doi:10.1186/S12915-024-01982-2/FIGURES/5 PubMed PMID: 39218872.
22. Cheryomushkina V, Guseva A, Talovskaya E, Astashenkov A. Dwarf subshrub morphological structure variety in species of the genus *Scutellaria* (Lamiaceae) under different growing conditions. *Taiwania.* 2022 Jan 25;67(1):146–54. doi:10.6165/TAI.2022.67.146
23. Guo F, Guan R, Sun X, Zhang C, Shan C, Liu M, et al. Integrated metabolome and transcriptome analyses of anthocyanin biosynthesis reveal key candidate genes involved in colour variation of *Scutellaria baicalensis* flowers. *BMC Plant Biol.* 2023 Dec 1;23(1). doi:10.1186/S12870-023-04591-3 PubMed PMID: 38097929.
24. Cha YP, Zhang J, Ma YM, Tong ZL, Wu Y, Luo L, et al. Variations in pollinator-mediated selection of floral traits across flowering times. *Journal of Plant Ecology.* 2023 Dec 1;16(6). doi:10.1093/JPE/RTAD024
25. Huang BH, Chen YW, Huang CL, Gao J, Liao PC. Diversifying selection of the anthocyanin biosynthetic downstream gene UFGT accelerates floral diversity of island *Scutellaria* species. *BMC Evol Biol.* 2016 Sep 17;16(1):191-. doi:10.1186/S12862-016-0759-0/TABLES/2 PubMed PMID: 27639694.
26. Costine B, Zhang M, Chhajed S, Pearson B, Chen S, Nadakuduti SS. Exploring native *Scutellaria* species provides insight into differential accumulation of flavones with medicinal properties. *Sci Rep.* 2022 Dec 1;12(1). doi:10.1038/s41598-022-17586-1 PubMed PMID: 35915209.
27. Lim J, Kim K, Kwon DY, Kim JK, Sathasivam R, Park SU. Effects of Different Solvents on the Extraction of Phenolic and Flavonoid Compounds, and Antioxidant Activities, in *Scutellaria baicalensis* Hairy Roots. *Horticulturae.* 2024 Feb 1;10(2):160. doi:10.3390/HORTICULTURAE10020160/S1
28. Wala M, Wróblewska K, Janda-Milczarek A, Dzi Ecioł M, Wala K, Wróblewska A, et al. The Effect of the Extraction Conditions on the Antioxidant Activity and Bioactive Compounds Content in Ethanolic Extracts of *Scutellaria baicalensis* Root. *Molecules* 2024, Vol 29, Page 4153. 2024 Sep 1;29(17):4153. doi:10.3390/MOLECULES29174153 PubMed PMID: 39275001.
29. Zhou P, Zuo L, Liu C, Xiong B, Li Z, Zhou X, et al. Unraveling spatial metabolome of the aerial and underground parts of *Scutellaria baicalensis* by matrix-assisted laser desorption/ionization mass

- spectrometry imaging. *Phytomedicine*. 2024 Jan 1;123:155259. doi:10.1016/J.PHYMED.2023.155259 PubMed PMID: 38096718.
30. Lawson SK, Satyal P, Setzer WN. Phytochemical Analysis of the Essential Oils From Aerial Parts of Four *Scutellaria* "Skullcap" Species Cultivated in South Alabama: *Scutellaria baicalensis* Georgi, *S. Barbata* D. Don, *S. Incana* Biehler, and *S. Lateriflora* L. *Nat Prod Commun*. 2021;16(8). doi:10.1177/1934578X211025930/ASSET/490C8F39-28D7-433A-AE22-55617117167E/ASSETS/IMAGES/LARGE/10.1177_1934578X211025930-FIG4.JPG
 31. Sun C, Xiao M, Cui B, Mu L, Zhang S, Zhang X, et al. Identification of flavonoid isomers in *Scutellaria baicalensis* using QSRR modeling. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2025 Mar 15;1254. doi:10.1016/J.JCHROMB.2025.124491 PubMed PMID: 39923614.
 32. Takeoka GR, Rodriguez DM, Dao L, Patterson R. Headspace Volatiles of *Scutellaria baicalensis* Georgi Flowers. *Journal of Essential Oil Bearing Plants*. 2009;12(4):435–42. doi:10.1080/0972060X.2009.10643741
 33. Askey BC, Liu D, Rubin GM, Kunik AR, Song YH, Ding Y, et al. Metabolite profiling reveals organ-specific flavone accumulation in *Scutellaria* and identifies a scutellarin isomer isoscutellarein 8-O- β -glucuronopyranoside. *Plant Direct*. 2021 Dec 1;5(12):e372. doi:10.1002/PLD3.372
 34. Zheng M, Fang Y, Zhao Q, Zheng M, Fang Y, Zhao Q. Comparative analysis of flavones from six commonly used *Scutellaria* species. *Medicinal Plant Biology* 2023 1:12. 2023;2(1). doi:10.48130/MPB-2023-0012
 35. Cheng Y, Cao W, Guo R, Chen R, Li X, Qian D, et al. A comparative study of the quality differences and seasonal dynamics of flavonoids between the aerial parts and roots of *Scutellaria barbata*. *Front Plant Sci*. 2024 Dec 2;15:1497664. doi:10.3389/FPLS.2024.1497664/TEXT
 36. Li HY, Wei WJ, Ma KL, Zhang JY, Li Y, Gao K. Phytotoxic neo-clerodane diterpenoids from the aerial parts of *Scutellaria barbata*. *Phytochemistry*. 2020 Mar 1;171:112230. doi:10.1016/J.PHYTOCHEM.2019.112230 PubMed PMID: 31923722.
 37. Kawka B, Kwiecień I, Ekiert H. Endogenous production of specific flavonoids and verbascoside in agar and agitated microshoot cultures of *Scutellaria lateriflora* L. and biotransformation potential. *Plant Cell Tissue Organ Cult*. 2020 Sep 1;142(3):471–82. doi:10.1007/S11240-020-01837-Y/TABLES/3
 38. Wilczańska A, Sparzak-Stefanowska B, Kokotkiewicz A, Jesionek A, Królicka A, Łuczkiwicz M, et al. Biotechnological strategies for controlled accumulation of flavones in hairy root culture of *Scutellaria lateriflora* L. *Scientific Reports* 2023 13:1. 2023 Nov 21;13(1):20422-. doi:10.1038/s41598-023-47757-7 PubMed PMID: 37990031.
 39. Li J, Wang YH, Smillie TJ, Khan IA. Identification of phenolic compounds from *Scutellaria lateriflora* by liquid chromatography with ultraviolet photodiode array and electrospray ionization tandem mass spectrometry. *J Pharm Biomed Anal*. 2012 Apr 7;63:120–7. doi:10.1016/J.JPBA.2012.01.027 PubMed PMID: 22342658.
 40. Stepanova AY, Solov'eva AI, Malunova MV, Salamaikina SA, Panov YM, Lelishentsev AA. Hairy Roots of *Scutellaria* spp. (Lamiaceae) as Promising Producers of Antiviral Flavones. *Molecules* 2021, Vol 26, Page 3927. 2021 Jun 27;26(13):3927. doi:10.3390/MOLECULES26133927 PubMed PMID: 34199058.
 41. Karimov A, Botirov EK. Flavonoids from the Aerial Part and Roots of *Scutellaria adenostegia*. *Chem Nat Compd*. 2015 Jul 22;51(4):764–5. doi:10.1007/S10600-015-1405-6/METRICS
 42. Musakhonovich KA, Mamadievich BK, Vladimirovna OY, Khozhiakbarovich BE, Akparalievich MA, Jalilovich AN. ESSENTIAL OIL COMPOSITION OF TWO SPECIES OF SCUTELLARIA AERIAL PARTS. *Химия растительного сырья*. 2021 Dec 14;(4):139–44. doi:10.14258/JCPRM.2021049121
 43. Chemesova II, Budantsev AL. F L A V O N O I D F R O M *ScuteUaria adsurgens*. *Chem Nat Compd*. 1994;30(2).
 44. Matsa M, Bardakci H, Gousiadou C, Kirmizibekmez H, Skaltsa H. Secondary metabolites from *Scutellaria albida* L. ssp. *velenovskiyi* (Rech. f.) Greuter & Burdet. *Biochem Syst Ecol*. 2019 Apr 1;83:71–6. doi:10.1016/J.BSE.2019.01.006
 45. Gousiadou C, Karioti A, Heilmann J, Skaltsa H. Iridoids from *Scutellaria albida* ssp. *albida*. *Phytochemistry*. 2007 Jul;68(13):1799–804. doi:10.1016/J.PHYTOCHEM.2007.04.014 PubMed PMID: 17532352.

46. Cicek M, Demirci B, Yilmaz G, Ketenoglu O, Baser KHC. Composition of the essential oils of subspecies of *scutellaria albida* L. from Turkey. *Journal of Essential Oil Research*. 2010;22(1):55–8. doi:10.1080/10412905.2010.9700265
47. Grzegorzczuk-Karolak I, Kuźma Ł, Wysokińska H. In vitro cultures of *Scutellaria alpina* as a source of pharmacologically active metabolites. *Acta Physiol Plant*. 2016 Jan 1;38(1):1–9. doi:10.1007/S11738-015-2024-3/FIGURES/4
48. Grzegorzczuk-Karolak I, Kuźma Ł, Wysokińska H. In vitro cultures of *Scutellaria alpina* as a source of pharmacologically active metabolites. *Acta Physiol Plant*. 2016 Jan 1;38(1):1–9. doi:10.1007/S11738-015-2024-3/FIGURES/4
49. Badalamenti N, Porrello A, Iardi V, Bruno M. The essential oil chemical composition of aerial parts of a new chemotype of *Scutellaria altissima* growing wild in North Macedonia. *Nat Prod Res*. 2025. doi:10.1080/14786419.2025.2566910 PubMed PMID: 41017527.
50. Grzegorzczuk-Karolak I, Kuźma Ł, Wysokińska H. Study on the chemical composition and antioxidant activity of extracts from shoot culture and regenerated plants of *Scutellaria altissima* L. *Acta Physiol Plant*. 2015 Jan 1;37(1):1736-. doi:10.1007/S11738-014-1736-0/TABLES/5
51. (PDF) HPLC analysis of flavonoids from *Scutellaria altissima* [Internet]. [cited 2026 May 2]. Available from: https://www.researchgate.net/publication/335034334_HPLC_analysis_of_flavonoids_from_Scutellaria_altissima
52. Miyaichi Y, Hanamitsu E, Kizu H, Tomimori T. Studies on the Constituents of *Scutellaria* Species (XXII). Constituents of the Roots of *Scutellaria amabilis* HARA. *Chem Pharm Bull (Tokyo)*. 2006 Apr;54(4):435–41. doi:10.1248/CPB.54.435 PubMed PMID: 16595941.
53. Fang QL, Qiao X, Yin X qing, Zeng Y cheng, Du C hong, Xue Y mei, et al. Flavonoids from *Scutellaria amoena* C. H. Wright alleviate mitochondrial dysfunction and regulate oxidative stress via Keap1/Nrf2/HO-1 axis in rats with high-fat diet-induced nonalcoholic steatohepatitis. *Biomedicine & Pharmacotherapy*. 2023 Feb 1;158:114160. doi:10.1016/J.BIOPHA.2022.114160 PubMed PMID: 36571996.
54. Shock CC, Poudel A, Satyal P, Setzer WN. Chemical Compositions of *Scutellaria* Essential Oils Cultivated in Eastern Oregon: *S. angustifolia*, *S. baicalensis*, *S. barbata*, and *S. lateriflora*. *Plants*. 2026 Apr 1;15(7):1075. doi:10.3390/PLANTS15071075/S1
55. Gharari Z, Bagheri K, Derakhshani B, Sharafi A. HPLC-DAD-ESI/MSn analysis of phenolic components of *Scutellaria araxensis*, *S. bornmuelleri* and *S. orientalis*. *Nat Prod Res*. 2022;36(9):2440–5. doi:10.1080/14786419.2020.1837810/ASSET/E6EFF6DF-0024-4661-BFF8-AB7963A1A901/ASSETS/IMAGES/GNPL_A_1837810_UF0001_C.JPG PubMed PMID: 33179516.
56. Gharari Z, Bagheri K, Danafar H, Sharafi A. Chemical Composition and Antimicrobial Activity of *Scutellaria araxensis* Essential Oil from Iran. *Chem Nat Compd*. 2020 Jul 1;56(4):745–7. doi:10.1007/S10600-020-03137-5/TABLES/2
57. Gharari Z, Bagheri K, Sharafi A. Fractional analysis of dichloromethane extract of *Scutellaria araxensis* Grossh root and shoot by HPLC-PDA-ESI-MSn. *Nat Prod Res*. 2022;36(15):4031–5. doi:10.1080/14786419.2021.1903003 PubMed PMID: 33764217.
58. Costine B, Zhang M, Chhajed S, Pearson B, Chen S, Nadakuduti SS. Exploring native *Scutellaria* species provides insight into differential accumulation of flavones with medicinal properties. *Sci Rep*. 2022 Dec 1;12(1). doi:10.1038/S41598-022-17586-1 PubMed PMID: 35915209.
59. Yılmaz G, Çiçek M, Demirci B, Başer KHC. Essential oil compositions of subspecies of *Scutellaria brevibracteata* Stapf from Turkey. *Journal of Essential Oil Research*. 2019 Jul 4;31(4):255–62. doi:10.1080/10412905.2019.1579762
60. Dogan Z, Telli G, Cahide Tel B, Saracoglu I. *Scutellaria brevibracteata* Stapf and active principles with anti-inflammatory effects through regulation of NF-κB/COX-2/iNOS pathways [Internet]. 2022. doi:10.1016/j.fitote.2022.105159
61. Gharari Z, Bagheri K, Danafar H, Sharafi A. Enhanced flavonoid production in hairy root cultures of *Scutellaria bornmuelleri* by elicitor induced over-expression of MYB7 and FNSII2 genes. *Plant Physiology and Biochemistry*. 2020 Mar 1;148:35–44. doi:10.1016/J.PLAPHY.2020.01.002 PubMed PMID: 31926388.

62. Gharari Z, Shabani H, Bagheri K, Sharafi A. Phytochemical composition profile of *Scutellaria bornmuelleri* methanolic extract using GC-MS analysis. *Future Natural Products*. 2022 Jun 1;8(1):7–14. doi:10.34172/FNP.2022.03
63. Takeoka GR, Dao L, Rodriguez DM, Patterson R. Headspace volatiles of *scutellaria californica* a. Gray flowers. *Journal of Essential Oil Research*. 2008;20(2):169–71. doi:10.1080/10412905.2008.9699982
64. Giuliani C, Bottoni M, Ascrizzi R, Milani F, Flamini G, Fico G. *Scutellaria caucasica* A. Ham.: Morphological features and headspace characterization. *Flora: Morphology, Distribution, Functional Ecology of Plants*. 2020 Aug 1;269. doi:10.1016/J.FLORA.2020.151638
65. Stojakowska A, Kisiel W. Secondary metabolites from a callus culture of *Scutellaria columnae*. *Fitoterapia*. 1999 Jun 1;70(3):324–5. doi:10.1016/S0367-326X(99)00022-2
66. Siddikov GU, Yuldashev MP, Batirov EK, Abdullaev S V. Flavonoids from *Scutellaria cordifrons* and *S. phyllostachya* roots. *Chem Nat Compd*. 2006;42(3):356–7. doi:10.1007/S10600-006-0121-7/METRICS
67. Turginov OT, Akbarova MH, Turginov OT, Akbarova MH. Distribution of the Species Genus *Scutellaria* L. (Lamiaceae) Flora of the Ferghana Valley. *Am J Plant Sci*. 2020 Oct 11;11(10):1533–44. doi:10.4236/AJPS.2020.1110111
68. Bruno M, Fazio C, Arnold NA. Neo-clerodane diterpenoids from *Scutellaria cypria*. *Phytochemistry*. 1996 May 1;42(2):555–7. doi:10.1016/0031-9422(96)00013-1
69. Dehkordi FJ, Kharazian N, Lorigooini Z. Characterization of flavonoid components in *scutellaria* L. Species (Lamiaceae) using fingerprinting analysis. *Acta Biol Crac Ser Bot*. 2020;62(1):79–96. doi:10.24425/abscsb.2020.131666
70. Ismail Ahmadi F, Fathollahi R, Dastan D. Phytochemical Constituents and Biological Properties of *Scutellaria Condensata* Subsp. *Pycnotricha*. *Journal of Applied Organometallic Chemistry*. 2022 Aug 1;2(3):119–28. doi:10.22034/JAOC.2022.154719
71. Sarikurku C, Sihoglu A, Kirkan B. LC-ESI-MS/MS-based phytochemical characterization and antioxidant – enzyme inhibitory correlation in *Scutellaria diffusa*. *Spectroscopy Letters*. 2026. doi:10.1080/00387010.2026.2650372
72. Cicek M, Demirci B, Yilmaz G, Baser KHC. Essential oil composition of three species of *Scutellaria* from Turkey. *Nat Prod Res*. 2011 Oct;25(18):1720–6. doi:10.1080/14786419.2010.512997 PubMed PMID: 21714762.
73. Tomimori T, Miyaiichi Y, Yashitaicaimoto YI, Kizu H, Namba T. Studies on the Nepalese Crude Drugs. XI. : On the Flavonoid Constituents of the Aerial Parts of *Scutellaria discolor* COLEBR. *Chem Pharm Bull (Tokyo)*. 1988 Sep 25;36(9):3654–8. doi:10.1248/CPB.36.3654
74. Shah M, Murad W, Rehman NU, Halim SA, Ahmed M, Rehman H, et al. Biomedical Applications of *Scutellaria edelbergii* Rech. f.: In Vitro and In Vivo Approach. *Molecules*. 2021 Jun 2;26(12):3740. doi:10.3390/MOLECULES26123740 PubMed PMID: 34205312.
75. Xiao K, Han QT, Zhang L, Dai SJ. Two new flavanone glycosides from *Scutellaria galericulata* with anti-inflammatory activities. *Phytochem Lett*. 2017 Jun 1;20:151–4. doi:10.1016/J.PHYTOL.2017.04.036
76. Zhang DW, Wang Y, Liu JH, Yue XD, Dai SJ. neo-Clerodane diterpenoids from *Scutellaria galericulata* and their anti-inflammatory activities. *Phytochem Lett*. 2026 Jun 1;73:104170. doi:10.1016/J.PHYTOL.2026.104170
77. Marrero Delange D, Morales Rico CL, Canavaciolo VG, Rodríguez Leyes EA, Pérez RS. Volatile Constituents from Leaves of Endemic *Scutellaria havanensis* Jacq. in Cuba. *Journal of Essential Oil-Bearing Plants*. 2013 Jun;16(3):368–71. doi:10.1080/0972060X.2013.794045
78. Yuldashev MP, Batirov EK, Malikov VM. Flavonoids of the epigeal part of *Scutellaria glabrata*. *Chem Nat Compd*. 1994 May;29(3):410–1. doi:10.1007/BF00630555
79. Dogan Z, Ishiuchi K, Makino T, Saracoglu I. New acylated iridoid glucosides from *Scutellaria glaphyrostachys* Rech.f. and chemotaxonomic importance for the genus *Scutellaria*. *Phytochem Lett*. 2019 Aug 1;32:157–61. doi:10.1016/J.PHYTOL.2019.06.004
80. Karimov AM, BE, K. СТРУКТУРНОЕ РАЗНООБРАЗИЕ И СТЕПЕНЬ ИЗУЧЕННОСТИ ФЛАВОНОИДОВ РОДА SCUTELLARIA L. chemistry of plant raw material. 2015. doi:10.14258/jcprm.201601962

81. Studies on the Nepalese Crude Drugs. XIII. On the Flavonoid and Iridoid Constituents of the Root of *Scutellaria grossa* WALL | CiNii Research [Internet]. [cited 2026 May 3]. Available from: <https://cir.nii.ac.jp/crid/1570291227531014912>
82. (PDF) ФЛАВОНОИДИ SCUTELLARIA HAEMATOCHELORA JUZ. И S. OCELLATA JUZ. [Internet]. [cited 2026 May 3]. Available from: https://www.researchgate.net/publication/344728555_FLAVONOIDY_SCUTELLARIA_HAEMATOCHELORA_JUZ_I_S_OCELLATA_JUZ
83. Bai M, Zheng CJ, Wu SY, Chen GY, Song XP, Han CR. Chemical constituents from *Scutellaria hainanensis* C. Y. Wu. *Biochem Syst Ecol.* 2019 Feb 1;82:1–12. doi:10.1016/J.BSE.2018.10.007
84. Bardakci H, Skaltsa H, Milosevic-Ifantis T, Lazari D, Hadjipavlou-Litina D, Yeşilada E, et al. Antioxidant activities of several *Scutellaria* taxa and bioactive phytoconstituents from *Scutellaria hastifolia* L. *Ind Crops Prod.* 2015 Dec 23;77:196–203. doi:10.1016/J.INDCROP.2015.08.027
85. Kamoldinov KS, Eshbakova KA, Bobakulov KM. Constituents of *Scutellaria holosericea*. *Chem Nat Compd.* 2012 Nov 17;48(5):889–90. doi:10.1007/S10600-012-0413-Z/METRICS
86. Miyazawa M, Nomura M, Marumoto S, Mori K. Characteristic odor components of essential oil from *Scutellaria laeteviolacea*. *J Oleo Sci.* 2013;62(1):51–6. doi:10.5650/JOS.62.51 PubMed PMID: 23357818.
87. Diao HM, Hao Y, Li J, Ling HW, Shi KX, Zhang W, et al. Flavonoids from *Scutellaria likiangensis* Diels and their antimalarial activities. *Fitoterapia.* 2023 Jan 1;164:105357. doi:10.1016/J.FITOTE.2022.105357 PubMed PMID: 36460204.
88. Firouznia A, Rustaiyana A, Masoudi S, Rahimizade M, Bigdeli M, Tabatabaei-Anaraki M. Volatile Constituents of *Salvia limbata*, *Stachys turcomanica*, *Scutellaria litwinowii* and *Hymenocrater elegans* Four Lamiaceae Herbs from Iran. *Journal of Essential Oil Bearing Plants.* 2009;12(4):482–9. doi:10.1080/0972060X.2009.10643748
89. Nikbin M, Kazemipour N, Maghsoodlou MT, Valizadeh J, Sepehrimanesh M, Davarimanesh A. Mineral elements and essential oil contents of *Scutellaria luteo-caerulea* Bornm. & Snit. *Avicenna J Phytomed.* 2014 May;4(3):182. PubMed PMID: 25050316.
90. Mamadalieva NZ, Sharopov F, Satyal P, Azimova SS, Wink M. Composition of the essential oils of three Uzbek *Scutellaria* species (Lamiaceae) and their antioxidant activities. *Nat Prod Res.* 2017;31(10):1172–6. doi:10.1080/14786419.2016.1222383 PubMed PMID: 27545726.
91. Mamadalieva NZ, Herrmann F, El-Readi MZ, Tahrani A, Hamoud R, Egamberdieva DR, et al. Flavonoids in *Scutellaria immaculata* and *S. ramosissima* (Lamiaceae) and their biological activity. *Journal of Pharmacy and Pharmacology.* 2011 Oct 1;63(10):1346–57. doi:10.1111/J.2042-7158.2011.01336.X PubMed PMID: 21899551.
92. He L, Zhang Z, Lu L, Liu Y, Li S, Wang J, et al. Rapid identification and quantitative analysis of the chemical constituents in *Scutellaria indica* L. by UHPLC–QTOF–MS and UHPLC–MS/MS. *J Pharm Biomed Anal.* 2016 Jan 5;117:125–39. doi:10.1016/J.JPBA.2015.08.034 PubMed PMID: 26350559.
93. Ngu TN, To DC, Ngoc TVT, Thi BHD. Chemical Constituents from the Whole Plant of *Scutellaria indica*. *HPU2 Journal of Science: Natural Sciences and Technology.* 2022 Dec 28;1(2):44–51. doi:10.56764/HPU2.JOS.2022.2.1.44-51
94. Karimov AM, Slobodyanyuk TN, Botirov EK. Flavonoids from the Aerial Part of *Scutellaria intermedia*. *Chem Nat Compd.* 2017;53(4):745–6. doi:10.1007/S10600-017-2107-Z
95. Ismailov AI, Karimdzhanov AK, Khudaibergenov T, Latvineuko VI, Popova TP. Phenolic compounds of *Scutellaria iscanderi*. *Chem Nat Compd.* 1995;31(3):414–414. doi:10.1007/BF01165218/METRICS
96. Yunusov and Tashkent. *Journal of Science and Mathematic* [Internet]. 2025 [cited 2026 May 3]. View of Phytochemical Influence of *Scutellaria iscanderi* L. on Zinc Oxide Nanoparticle Biosynthesis. Available from: <https://ejournal.upsi.edu.my/index.php/JSML/article/view/11853/6060>
97. Gharari Z, Bagheri K, Danafar H, Sharafi A. Simultaneous determination of baicalein, chrysin and wogonin in four Iranian *Scutellaria* species by high performance liquid chromatography. *J Appl Res Med Aromat Plants.* 2020 Mar 1;16:100232. doi:10.1016/J.JARMAP.2019.100232
98. Yuldashev MP, Karimov A. Flavonoids of *Scutellaria ocellata* and *S. nepetoides*. *Chem Nat Compd.* 2001;37(5):431–3. doi:10.1023/A:1014411108068/METRICS

99. Shah M, Shahab M, Ullah S, Bibi S, Rahman NU, Jamil J, et al. Exploring the aroma profile and biomedical applications of *Scutellaria nuristanica* Rech. F.: A new insight as a natural remedy. *Phytomedicine*. 2024 Oct 1;133:155928. doi:10.1016/J.PHYMED.2024.155928 PubMed PMID: 39126924.
100. Rajendran N, Subramaniam S, Christena LR, Muthuraman MS, Subramanian NS, Pemiah B, et al. Antimicrobial flavonoids isolated from Indian medicinal plant *Scutellaria oblonga* inhibit biofilms formed by common food pathogens. *Nat Prod Res*. 2016;30(17):2002–6. doi:10.1080/14786419.2015.1104673 PubMed PMID: 26508034.
101. Yılmaz G, Çiçek M, Demirci B, Başer KHC. Composition of the essential oils of five subspecies of *Scutellaria orientalis* from Turkey. *Journal of Essential Oil Research*. 2020 Sep 2;32(5):429–35. doi:10.1080/10412905.2020.1796832
102. Sina İçen M, Arabacı T, Kösteki S, Gürhan İ. Chemical Composition of the Essential Oil of *Scutellaria orientalis* L. subsp. *virens* (Boiss. &Kotschy) J. R. Edm. from Turkey Türkiye’de yetişen. *J Biol & Chem*. 2016;44(1):25–8. doi:10.15671/HJBC.20164417563
103. Muradov MT, Khurramov AR, Bobakulov KM, Karimov AM, Botirov EK. Constituents from the Aerial Part of *Scutellaria oxystegia*. *Chem Nat Compd*. 2023 Sep 1;59(5):939–40. doi:10.1007/S10600-023-04156-8
104. Lawrence BM, Hogg JW, Terhune SJ, Morton JK, Gill LS. Terpenoid composition of some Canadian Labiatae. *Phytochemistry*. 1972 Aug 1;11(8):2636–8. doi:10.1016/S0031-9422(00)88570-2
105. Delazar A, Nazemiyeh H, Afshar F, Barghi N, Esnaashari S, Asgharian P. Chemical compositions and biological activities of *Scutellaria pinnatifida* A. Hamilt aerial parts. *Res Pharm Sci*. 2017 Jun 1;12(3):187. doi:10.4103/1735-5362.207199 PubMed PMID: 28626476.
106. Heydari F, Tavakoli S, Shokravi A, Ahmadi S, Delnavazi MR, Heydari F, et al. A Study of Karabaghian Skullcap (*Scutellaria platystegia* Juz.): Antioxidant and Antibacterial Activity Assays, Essential Oil Analysis, and Isolation of Its Phenolic Compounds. *Jundishapur Journal of Natural Pharmaceutical Products* 2022 17:2. 2022 May 31;17(2):e118896. doi:10.5812/JJNPP-118896
107. ERSÖZ T, HARPÜT ÜŞ, SARACOĞLU İ, ÇALIŞ İ, OGIHARA Y. Phenolic Compounds from *Scutellaria pontica*. *Turk J Chem*. 2002 Jan 1;26(4):581–8. doi:-
108. Bhat G, Ganai BA, Shawl AS. New phenolics from the root of *Scutellaria prostrata* JACQ. ex BENTH. *Nat Prod Res*. 2014;28(20):1685–90. doi:10.1080/14786419.2014.939082 PubMed PMID: 25040064.
109. Bhat G, Lone SH, Rather MA, Shawl AS. Isolation, bioevaluation and RP-HPLC method development for the chemical constituents of aerial parts of *Scutellaria prostrata* Jacq. ex Benth. *South African Journal of Botany*. 2022 Aug 1;148:720–6. doi:10.1016/J.SAJB.2022.05.030
110. Denikeeva MF, Litvinenko VI, Borodin LI. Flavonoid compounds of *Scutellaria przewalskii*. *Chem Nat Compd*. 1970 Sep 1;6(5):552–5. doi:10.1007/BF00563438/METRICS
111. Solov’eva AI, Stepanova AY, Panov YM, Gladkov EA. Metabolic Characteristics of Hairy Root Clones of *Scutellaria pycnoclada* and *Scutellaria baicalensis*. *Processes*. 2023 Jul 1;11(7):2102. doi:10.3390/PR11072102/S1
112. Shah M, Shahab M, Ullah S, Bibi S, Rahman NU, Jamil J, et al. Exploring the aroma profile and biomedical applications of *Scutellaria nuristanica* Rech. F.: A new insight as a natural remedy. *Phytomedicine*. 2024 Oct 1;133:155928. doi:10.1016/J.PHYMED.2024.155928 PubMed PMID: 39126924.
113. Islam MN, Downey F, Ng CKY. Comparative analysis of bioactive phytochemicals from *Scutellaria baicalensis*, *Scutellaria lateriflora*, *Scutellaria racemosa*, *Scutellaria tomentosa* and *Scutellaria wrightii* by LC-DAD-MS. *Metabolomics*. 2011 Sep 25;7(3):446–53. doi:10.1007/S11306-010-0269-9/TABLES/2
114. Ya-In Su YHZYC. Isolation and elucidation of antioxidant constituents from acetone extract in root of *Scutellaria rehderiana* | Request PDF [Internet]. 2004 [cited 2026 May 4]. Available from: https://www.researchgate.net/publication/8152832_Isolation_and_elucidation_of_antioxidant_constituents_from_acetone_extract_in_root_of_Scutellaria_rehderiana
115. Lin YL, Kuo YH, Cheng MC, Wang Y. Structures of Scutellones D and E Determined from X-Ray Diffraction, Spectral and Chemical Evidence. Neoclerodane-Type Diterpenoids from *Scutellaria rivularis* WALL. *Chem Pharm Bull (Tokyo)*. 1988 Jul 25;36(7):2642–6. doi:10.1248/CPB.36.2642

116. Lin CC, Shieh DE. The Anti-inflammatory Activity of *Scutellaria rivularis* Extracts and Its Active Components, Baicalin, Baicalein and Wogonin. <https://doi.org/10.1142/S0192415X96000050>. 2012 Apr 5;24(1):31–6. doi:10.1142/S0192415X96000050 PubMed PMID: 8739179.
117. Rosselli S, Bruno M, Simmonds MSJ, Senatore F, Rigano D, Formisano C. Volatile constituents of *Scutellaria rubicunda* Hornem subsp. *linnaeana* (Caruel) Rech. (Lamiaceae) endemic in Sicily. *Biochem Syst Ecol*. 2007 Nov 1;35(11):797–800. doi:10.1016/J.BSE.2007.03.021
118. Watanabe M, Yahagi T, Kamikura R, Kotani H, Miyake K, Matsuzaki K. Methoxyflavones isolated from the whole plant of *Scutellaria rubropunctata* Hayata var. *rubropunctata* promote osteoblast differentiation in MC3T3-E1 cells. *J Nat Med*. 2023 Sep 1;77(4):748–60. doi:10.1007/S11418-023-01716-8 PubMed PMID: 37329417.
119. Dogan Z, Kutluay VM, Genc Y, Saracoglu I. Interactions between phenolic constituents of *Scutellaria salviifolia* and key targets associated with inflammation: network pharmacology, molecular docking analysis and in vitro assays. *J Biomol Struct Dyn*. 2023;41(4):1281–94. doi:10.1080/07391102.2021.2019119 PubMed PMID: 34939529.
120. Miyaichi Y, Imoto Y, Tomimori T, Namba T. Studies on the Nepalese Crude Drugs. IX. : On the Flavonoid Constituents of the Root of *Scutellaria scandens* BUCH.-HAM. ex D. DON. *Chem Pharm Bull (Tokyo)*. 1988 Jul 25;36(7):2371–6. doi:10.1248/CPB.36.2371
121. Melkani AB, Nailwal M, Mohan L, Pant CC, Dev V. Steam volatile oil from *Scutellaria repens* Buch-Ham. ex D. Don; its composition and antibacterial activity. *Journal of Essential Oil Research*. 2013 Oct 1;25(5):368–71. doi:10.1080/10412905.2013.782474
122. Nurbyek S, Buyankhishig B, Suganuma K, Ishikawa Y, Kutsuma M, Abe M, et al. Phytochemical investigation of *Scutellaria scordiifolia* and its trypanocidal activity. *Phytochemistry*. 2023 May 1;209:113615. doi:10.1016/J.PHYTOCHEM.2023.113615 PubMed PMID: 36828100.
123. Esquivel B, Calderón JS, Flores E. A neo-clerodane diterpenoid from *Scutellaria seleriana*. *Phytochemistry*. 1998 Jan 1;47(1):135–7. doi:10.1016/S0031-9422(97)88556-1
124. Glandular Trichomes Morphology, Chemical Composition and Antimicrobial Activity of the Essential Oil of Three Endemic *Scutellaria* Taxa (Lamiaceae) | *Asian Journal of Chemistry [Internet]*. [cited 2026 May 3]. Available from: <https://asianpubs.org/index.php/ajchem/article/view/9794>
125. Zhu X, Han C, Gao T, Shao H. Chemical Composition, Phytotoxic and Antimicrobial Activities of the Essential Oil of *Scutellaria strigillosa* Hemsley. *Journal of Essential Oil Bearing Plants*. 2016 Apr 2;19(3):664–70. doi:10.1080/0972060X.2014.1000389
126. Bai C, Xu J, Cao B, Li X, Li G. Transcriptomic analysis and dynamic expression of genes reveal flavonoid synthesis in *Scutellaria viscidula*. *Acta Physiol Plant*. 2018 Sep 1;40(9):161-. doi:10.1007/S11738-018-2733-5/TABLES/5
127. Valarezo E, Castillo A, Guaya D, Morocho V, Malagón O. Chemical composition of essential oils of two species of the Lamiaceae family: *Scutellaria volubilis* and *Lepechinia paniculata* from Loja, Ecuador. *Journal of Essential Oil Research*. 2012 Feb;24(1):31–7. doi:10.1080/10412905.2012.645638
128. Li H, Tang S. Baicalin attenuates diet-induced obesity partially through promoting thermogenesis in adipose tissue. *Obes Res Clin Pract*. 2021 Sep 1;15(5):485–90. doi:10.1016/J.ORCP.2021.08.003 PubMed PMID: 34465552.
129. Dai J, Liang K, Zhao S, Jia W, Liu Y, Wu H, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. *Proc Natl Acad Sci U S A*. 2018 Jun 26;115(26):E5896–905. doi:10.1073/PNAS.1801745115 PubMed PMID: 29891721.
130. Zhang Y, Zhang Z, Zhang Y, Wu L, Gao L, Yao R, et al. Baicalin promotes the activation of brown and white adipose tissue through AMPK/PGC1 α pathway. *Eur J Pharmacol*. 2022 May 5;922:174913. doi:10.1016/J.EJPHAR.2022.174913 PubMed PMID: 35337814.
131. Zhang Z, Wang R, Cai J, Li X, Feng X, Xu S, et al. Baicalin alleviates lipid accumulation in adipocytes via inducing metabolic reprogramming and targeting Adenosine A1 receptor. *Toxicol*. 2025 Apr 1;258:108339. doi:10.1016/J.TOXICON.2025.108339 PubMed PMID: 40188992.
132. Seo MJ, Choi HS, Jeon HJ, Woo MS, Lee BY. Baicalein inhibits lipid accumulation by regulating early adipogenesis and m-TOR signaling [Internet]. 2014. doi:10.1016/j.fct.2014.02.009

133. Dunkhunthod B, Thumanu K, Eumkeb G. Application of FTIR microspectroscopy for monitoring and discrimination of the anti-adipogenesis activity of baicalein in 3T3-L1 adipocytes [Internet]. 2017. doi:10.1016/j.vibspec.2017.01.006
134. Zhang S, Yang S, Kong B, Zhang Q, Zhou Z, Zhao W, et al. Baicalein alleviates Western diet-induced obesity via metabolically activated adipose tissue macrophages by inducing Nrf2. *J Nutr Biochem*. 2026 Apr 15;110381. doi:10.1016/J.JNUTBIO.2026.110381
135. Li S, Shao S, Zhang Z, Wang Z, Han X, Jia X, et al. V8, a lysosomotropic wogonin derivative, alleviates hepatic steatosis by modulating GDF15-dependent mitochondrial homeostasis. *Free Radic Biol Med*. 2026 Jan 1;242:92–107. doi:10.1016/J.FREERADBIOMED.2025.10.274 PubMed PMID: 41138960.
136. Bak EJ, Kim J, Choi YH, Kim JH, Lee DE, Woo GH, et al. Wogonin ameliorates hyperglycemia and dyslipidemia via PPAR α activation in db/db mice. *Clinical Nutrition*. 2014 Feb 1;33(1):156–63. doi:10.1016/J.CLNU.2013.03.013 PubMed PMID: 23623334.
137. Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, et al. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPAR α /AdipoR2, in vivo and in vitro. *Biomedicine & Pharmacotherapy*. 2017 Jul 1;91:621–31. doi:10.1016/J.BIOPHA.2017.04.125 PubMed PMID: 28486193.
138. Jiang G, Chen D, Li W, Liu C, Liu J, Guo Y. Effects of wogonoside on the inflammatory response and oxidative stress in mice with nonalcoholic fatty liver disease. *Pharm Biol*. 2020;58(1):1177–83. doi:10.1080/13880209.2020.1845747 PubMed PMID: 33253604.
139. Gao YZ, Zhao LF, Ma J, Xue WH, Zhao H. Protective mechanisms of wogonoside against Lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. *Eur J Pharmacol*. 2016 Jun 5;780:8–15. doi:10.1016/J.EJPHAR.2016.02.040 PubMed PMID: 26921756.
140. Lin Y, Ren N, Li S, Chen M, Pu P. Novel anti-obesity effect of scutellarein and potential underlying mechanism of actions. *Biomedicine & Pharmacotherapy*. 2019 Sep 1;117:109042. doi:10.1016/J.BIOPHA.2019.109042 PubMed PMID: 31228804.
141. Zhang X, Huo Z, Luan H, Huang Y, Shen Y, Sheng L, et al. Scutellarin ameliorates hepatic lipid accumulation by enhancing autophagy and suppressing IRE1 α /XBP1 pathway. *Phytotherapy Research*. 2022 Jan 1;36(1):433–47. doi:10.1002/PTR.7344 PubMed PMID: 34859513.
142. Park MY, Ha SE, Kim HH, Bhosale PB, Abusaliya A, Jeong SH, et al. Scutellarein Inhibits LPS-Induced Inflammation through NF- κ B/MAPKs Signaling Pathway in RAW264.7 Cells. *Molecules*. 2022 Jun 1;27(12). doi:10.3390/MOLECULES27123782 PubMed PMID: 35744907.
143. Cho W, Choi SW, Oh H, Abd El-Aty AM, Hacimuftuoglu A, Jeong JH, et al. Oroxylin-A alleviates hepatic lipid accumulation and apoptosis under hyperlipidemic conditions via AMPK/FGF21 signaling. *Biochem Biophys Res Commun*. 2023 Mar 12;648:59–65. doi:10.1016/J.BBRC.2023.01.090 PubMed PMID: 36736092.
144. Singh J, Kakkar P. Oroxylin A, a constituent of *Oroxylum indicum* inhibits adipogenesis and induces apoptosis in 3T3-L1 cells. *Phytomedicine*. 2014 Oct 15;21(12):1733–41. doi:10.1016/J.PHYMED.2014.08.014 PubMed PMID: 25442284.
145. Jiang Y, Jiang K, Sun P, Liu Y, Nie H. Oroxylin A ameliorates non-alcoholic fatty liver disease by modulating oxidative stress and ferroptosis through the Nrf2 pathway. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*. 2025 Jun 1;1870(5):159628. doi:10.1016/J.BBALIP.2025.159628 PubMed PMID: 40368273.
146. Choi JH, Yun JW. Chrysin induces brown fat-like phenotype and enhances lipid metabolism in 3T3-L1 adipocytes. *Nutrition*. 2016 Sep 1;32(9):1002–10. doi:10.1016/J.NUT.2016.02.007 PubMed PMID: 27133810.
147. Feng X, Qin H, Shi Q, Zhang Y, Zhou F, Wu H, et al. Chrysin attenuates inflammation by regulating M1/M2 status via activating PPAR γ . *Biochem Pharmacol*. 2014 Jun 15;89(4):503–14. doi:10.1016/J.BCP.2014.03.016 PubMed PMID: 24704474.
148. Pai SA, Martis EA, Munshi RP, Gursahani MS, Mestry SN, Juvekar AR. Chrysin mitigated obesity by regulating energy intake and expenditure in rats. *J Tradit Complement Med*. 2020 Nov 1;10(6):577–85. doi:10.1016/J.JTCME.2019.09.002
149. Feng X, Weng D, Zhou F, Owen YD, Qin H, Zhao J, et al. Activation of PPAR γ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization. *EBioMedicine*. 2016 Jul 1;9:61–76. doi:10.1016/J.EBIOM.2016.06.017 PubMed PMID: 27374313.

150. Yu H, Huang X, Zhu HH, Wang N, Xie C, Zhou YL, et al. Apigenin ameliorates non-eosinophilic inflammation, dysregulated immune homeostasis and mitochondria-mediated airway epithelial cell apoptosis in chronic obese asthma via the ROS-ASK1-MAPK pathway. *Phytomedicine*. 2023 Mar 1;111:154646. doi:10.1016/J.PHYMED.2023.154646 PubMed PMID: 36645975.
151. Mou A, Sun F, Tong D, Wang L, Lu Z, Cao T, et al. Dietary apigenin ameliorates obesity-related hypertension through TRPV4-dependent vasorelaxation and TRPV4-independent adiponectin secretion. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*. 2024 Dec 1;1870(8):167488. doi:10.1016/J.BBADIS.2024.167488 PubMed PMID: 39218272.
152. Xie Y, Berntsen HF, Zimmer KE, Ropstad E, Verhaegen S, Connolly L. Luteolin protects against adipogenic and lipogenic potency induced by human relevant mixtures of persistent organic pollutants (POPs) in the 3T3-L1 model. *Food and Chemical Toxicology*. 2023 Mar 1;173:113608. doi:10.1016/J.FCT.2023.113608 PubMed PMID: 36639049.
153. Baek Y, Lee MN, Wu D, Pae M. Luteolin reduces adipose tissue macrophage inflammation and insulin resistance in postmenopausal obese mice. *J Nutr Biochem*. 2019 Sep 1;71:72–81. doi:10.1016/J.JNUTBIO.2019.06.002 PubMed PMID: 31302373.
154. Na HY, Lee BC. *Scutellaria baicalensis* Alleviates Insulin Resistance in Diet-Induced Obese Mice by Modulating Inflammation. *Int J Mol Sci*. 2019 Feb 1;20(3):727. doi:10.3390/IJMS20030727 PubMed PMID: 30744038.
155. Ma L, Wang Y, Ren T, Pan L, Li X, Wang S, et al. *Scutellaria baicalensis* extract prevents metabolic dysfunction-associated steatotic liver disease by modulating the gut-liver axis in high-fat diet mice. *Phytochemistry*. 2026 Mar 1;243:114720. doi:10.1016/J.PHYTOCHEM.2025.114720 PubMed PMID: 41318014.
156. Sung YY, Kim SH, Kim DS. Combined *Phyllostachys pubescens* and *Scutellaria baicalensis* Prevent High-Fat Diet-Induced Obesity via Upregulating Thermogenesis and Energy Expenditure by UCP1 in Male C57BL/6J Mice. *Nutrients*. 2022 Feb 1;14(3):446. doi:10.3390/NU14030446/S1 PubMed PMID: 35276805.
157. Li ST, Xu D, Jia J, Zou W, Liu JY, Wang Y, et al. Structure and anti-inflammatory activity of neo-clerodane diterpenoids from *Scutellaria barbata*. *Phytochemistry*. 2023 Sep 1;213:113771. doi:10.1016/J.PHYTOCHEM.2023.113771 PubMed PMID: 37352949.
158. Liu HL, Kao TH, Shiau CY, Chen BH. Functional components in *Scutellaria barbata* D. Don with anti-inflammatory activity on RAW 264.7 cells. *J Food Drug Anal*. 2018 Jan 1;26(1):31–40. doi:10.1016/J.JFDA.2016.11.022 PubMed PMID: 29389569.
159. Kwiecień I, Miceli N, D'arrigo M, Marino A, Ekiert H. Antioxidant Potential and Enhancement of Bioactive Metabolite Production in In Vitro Cultures of *Scutellaria lateriflora* L. by Biotechnological Methods. *Molecules*. 2022 Feb 1;27(3). doi:10.3390/MOLECULES27031140 PubMed PMID: 35164404.
160. Long DM, Martinez J, Soumyanath A, Kretzschmar D. *Scutellaria lateriflora* Extract Supplementation Provides Resilience to Age-Related Phenotypes in *Drosophila melanogaster*. *Int J Mol Sci*. 2026 Jan 1;27(1):461. doi:10.3390/IJMS27010461/S1 PubMed PMID: 41516334.
161. Cuong TD, Hung TM, Lee JS, Weon KY, Woo MH, Min BS. Anti-inflammatory activity of phenolic compounds from the whole plant of *Scutellaria indica*. *Bioorg Med Chem Lett*. 2015 Mar 1;25(5):1129–34. doi:10.1016/J.BMCL.2014.12.055 PubMed PMID: 25637363.
162. Kim SW, Cuong TD, Hung TM, Ryoo S, Lee JH, Min BS. Arginase II inhibitory activity of flavonoid compounds from *Scutellaria indica*. *Arch Pharm Res*. 2013 Aug;36(8):922–6. doi:10.1007/S12272-013-0125-3 PubMed PMID: 23604721.
163. Zhang DW, Wang Y, Liu JH, Yue XD, Dai SJ. neo-Clerodane diterpenoids from *Scutellaria galericulata* and their anti-inflammatory activities. *Phytochem Lett*. 2026 Jun 1;73:104170. doi:10.1016/J.PHYTOL.2026.104170
164. Xiao K, Han QT, Zhang L, Dai SJ. Two new flavanone glycosides from *Scutellaria galericulata* with anti-inflammatory activities. *Phytochem Lett*. 2017 Jun 1;20:151–4. doi:10.1016/J.PHYTOL.2017.04.036

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s)

disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.